April 23, 2021 05:11 PM EDTUpdated April 26, 06:53 AM
FDA+
Coronavirus

J&J vac­ci­na­tions re­sume as FDA, CDC con­fi­dent in ben­e­fit-risk pro­file

Zachary Brennan

Senior Editor

The FDA and CDC on Fri­day evening lift­ed the pause on J&J vac­ci­na­tions af­ter de­cid­ing that a very rare but some­times fa­tal side ef­fect does …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Stem cell start­up spun out of George Church’s lab rais­es $75M

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times